Communiqués Roche Holding AG Swiss Exchange

Actions

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:06 12/05/2026			Varia. 5j.	Varia. 1 janv.
321,50 ^CHF	+0,66 %		+0,92 %	-2,04 %

16:20	Roche obtient le marquage CE pour son test sanguin Elecsys pTau217 dédié au diagnostic de la maladie d'Alzheimer	CI
07:46	Feu vert de Bruxelles à un test sanguin de Roche dans la maladie d'Alzheimer

30/04	Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026	BU
24/04	Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign	BU
22/04	Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD	AQ
22/04	Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS	BU
21/04	Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD	BU
21/04	CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus	BU